1. Introduction {#s0005}
===============

The cytokine receptor-JAK-STAT pathway is a key signaling pathway during myelopoiesis. JAK2^V617F^ mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation that allows a cytokine-independent growth of megakaryocytes [@bib1]. Although it is accepted that JAK2^V617F^ drives clonal proliferation in ET, less is known about what factors influence the onset and development of the disease [@bib2]. JAK2 V617F mutation may also be present in individuals without signs of myeloprolifrative neoplasm (MPNs), but its the significance is still not clear [@bib3], [@bib4]. In general population JAK2 V617F mutation is associated with increased morbidity and mortality, although only present in 18 of 10 507 (0,2%) persons [@bib5]. Immune thrombocytopenia (ITP) is an acquired autoimmune disorder of increased platelet (PLT) destruction and decreased platelet production, that may be associated to bleeding, especially in the skin and the mucosa [@bib6]. ITP can be primary (80%) whereas other 20% occurs in the setting of lymphoproliferative disorders; systemic lupus erithematosus, or other autoimmune disorders; infections such as hepatitis C, HIV, and *Helicobacter pylori*. ET and ITP are different blood diseases with PLT counts at opposite extremes. So far, only 2 previous reports described ET following ITP [@bib7], [@bib8]. Hereby we describe a third case of ET diagnosed 13 years after ITP diagnosis. To our best knowledge, for the first time, we retrospectively showed the presence of a JAK2^V617F^ clone since the onset of ITP.

2. Case report {#s0010}
==============

In March 2004, a 72 year old woman suffering from rheumatoid arthritis, presented with petechiae, ecchymoses, epistaxis and a platelet (PLT) count of 13,000/μL was diagnosed with ITP ([Fig. 1](#f0005){ref-type="fig"}). White blood cell count (WBC) and hemoglobin (Hb) were within the normal ranges. Coagulation tests were normal. Tests for viral B and C hepatitis, CMV, and HIV were all negative. Bone marrow aspirate showed increased megakaryocytes and normal myeloid/erythroid ratio ([Fig. 2](#f0010){ref-type="fig"}A). Treatment with high dose prednisone (1 mg/Kg) was started with good PLT response (154,000/μL), but the drug was not well tolerated due to arterial hypertension and high blood sugar value. After 1 month prednisone was tapered and stopped in July. However, the platelet count fell and bleeding symptoms recurred. Prednisone was reinitiated in combination with immunoglobulin (400 mg/Kg for 5 days), obtaining only a transient response. Due to poor efficacy and tolerance, in March 2005, the patient underwent splenectomy, achieving a rapid normalization of PLT count (354,000/μL). Over the following 3 years PLT count increased to 700,000/μL but this was interpreted as a consequence of splenectomy; only treatment with aspirin was prescribed. Thereafter, the patient was lost to follow-up. After 9 years, in January 2017, the patient (age 85) was again referred to our department by her general practitioner owing to a PLT count of 1100,000/μL. A bone marrow trephine was performed, showing increased cellularity and several clusters of large to giant mature megacaryocytes with folded nuclei ([Fig. 2](#f0010){ref-type="fig"}B). A qualitative polymerase chain reaction (ASO-PCR) analysis demonstrated the presence of JAK2^V617F^ mutation in her peripheral blood. An allele burden (AB) of 27% was obtained by quantitative real-time polymerase chain reaction (qRT-PCR) using JAK2MutaQuant™ (Ipsogen Inc.,Qiagen Germany). We retrospectively analyzed the presence of JAK2^V617F^ mutation in the bone marrow smear of 2004: genomic DNA was recovered from a stained smear by scraping off the cells into a tube using a scalpel blade for manual extraction using the DNA blood mini kit (Qiagen, Germany) according to the manufacturer\'s instructions. The AB in 2004 was 3%. Based on WHO 2008 criteria [@bib9] the patient was diagnosed with ET and treated with Hydroxyurea (HU) 500 mg/die. PLT count decreased progressively until reaching normal range in August 2017. Currently the patient is doing well on the same dosage of HU.Fig. 1**:** Clinical outcome and platelet (PLT) count in a ITP patient associated with 3% of a JAK2^V617F^ allele burden (AB) followed ET with 27% of AB after 13 years.Fig. 1Fig. 2**A:** Bone marrow film of ITP diagnosed in 2004 (magnification 20×). Megakaryocytes are diffuse and slightly increased in number, with normal features.**B.** Bone marrow trephine of ET diagnosed in 2017 (magnification 20×). Clusters of large to giant mature megacaryocytes with folded nuclei.Fig. 2

3. Discussion {#s0015}
=============

JAK2^V617F^ represents a driving mutation, and almost all healthy individuals carrying it develop a MPN within 5--9 years [@bib10]. Nevertheless, the factors that influence the development of disease are poorly understood. An association between previous autoimmune disease and increased risk of MPN has been suggested [@bib11]. Huang et al. suggested the possibility of the coexistence of a clonal MPN with low JAK2^V617F^ allele burden and autoimmune-associated cytopenia, where thrombocytosis was probably masked by immune-mediated cellular destruction in the spleen pre-operatively, but data on JAK2^V617F^ at ITP onset nor bone marrow finding at ET transformation were not available [@bib7]. Notably, in our experience as well, progressive thrombocytosis developed after splenectomy. Sobas et al. reported data on bone marrow trephine in a case of JAK2^V617F^ positive ET 11 years after ITP, but mutation status at ITP diagnosis was not available. An inverted case of ITP following JAK2^V617F^ ET was also reported [@bib12]. For the first time we retrospectively analyzed the JAK2^V617F^ AB at ITP onset occurred 13 years before the ET diagnosis and found the presence of a small clone JAK2^V617F^ positive clone (3%) raised to 27% in the following years. All described cases of ET following ITP are associated with JAK2^V617F^ mutation and no reports are known with Calreticuline or MPL. The association of ET and ITP could suggest similar pathogenetic mechanisms that should be further investigated.

4. Conclusion {#s0020}
=============

In conclusion, splenectomy and autoimmunity might be factors influencing the development of MPN and JAK2^V617F^ mutation status analysis could be suggested to those ITP patients candidate to splenectomy or treatment with new thrombopoietin receptor agonists.
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